SCHEMBL16749436

SCHEMBL16749436

COC(=O)C1N(C(=O)OC(C)(C)C)CC(F)C1(C)C

nearest known ligand 0.35

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 2/20 0.35
NR1H3 Q13133 1/20 0.35
CCR2 P41597 2/20 0.35
PTPN1 P18031 1/20 0.34
PDE4B Q07343 1/20 0.34
MAPK1 P28482 1/20 0.33
EPHX2 P34913 1/20 0.32
CHRM2 P08172 1/20 0.32
CHRM1 P11229 1/20 0.32
CHRM3 P20309 1/20 0.32
DGAT1 O75907 1/20 0.32
USP30 Q70CQ3 1/20 0.31
TSHR P16473 1/20 0.31
HSD17B10 Q99714 1/20 0.31
EPHX1 P07099 1/20 0.31
CYP1A2 P05177 1/20 0.31
POLB P06746 1/20 0.31
CYP3A4 P08684 1/20 0.31
CYP2C19 P33261 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL875863 0.84 CHRM2 (0.36) NR1H2NR1H3CCR2PTPN1PDE4B
SCHEMBL882907 0.84 CHRM2 (0.36) NR1H2NR1H3CCR2PTPN1PDE4B
SCHEMBL8288617 0.84 CHRM2 (0.36) NR1H2NR1H3CCR2PTPN1PDE4B
SCHEMBL30484622 0.84 CHRM2 (0.36) NR1H2NR1H3CCR2PTPN1PDE4B
SCHEMBL3430059 0.77 PDE4B (0.33) NR1H2NR1H3CCR2PTPN1PDE4B
SCHEMBL16749570 0.75 NR1H2 (0.42) NR1H2CHRM2CHRM1CHRM3CYP3A4
SCHEMBL16749557 0.75 NR1H2 (0.33) NR1H2CCR2EPHX2CHRM2CHRM1
SCHEMBL30484644 0.75 PDE4B (0.32) NR1H2NR1H3PTPN1PDE4B
SCHEMBL5495474 0.74 PTPN1 (0.34) NR1H2NR1H3PTPN1PDE4BEPHX2
SCHEMBL5379806 0.74 PTPN1 (0.34) NR1H2NR1H3PTPN1PDE4BEPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3071564-B1 DIHYDROPYRIMIDINE COMPOUNDS AND THEIR APPLICATION IN PHARMACEUTICALS SUNSHINE LAKE PHARMA CO LTD (CN) 2020-08-05 EP disclosed
EP-3071564-B1 DIHYDROPYRIMIDINE COMPOUNDS AND THEIR APPLICATION IN PHARMACEUTICALS SUNSHINE LAKE PHARMA CO LTD (CN) 2020-08-05 EP disclosed
US-9498479-B2 Dihydropyrimidine compounds and their application in pharmaceuticals SUNSHINE LAKE PHARMA CO., LTD. (CN) 2016-11-22 US disclosed
US-9498479-B2 Dihydropyrimidine compounds and their application in pharmaceuticals SUNSHINE LAKE PHARMA CO., LTD. (CN) 2016-11-22 US disclosed
US-9498479-B2 Dihydropyrimidine compounds and their application in pharmaceuticals SUNSHINE LAKE PHARMA CO., LTD. (CN) 2016-11-22 US disclosed
US-20160206616-A1 DIHYDROPYRIMIDINE COMPOUNDS AND THEIR APPLICATION IN PHARMACEUTICALS SUNSHINE LAKE PHARMA CO., LTD. (CN) 2016-07-21 US disclosed
US-20160206616-A1 DIHYDROPYRIMIDINE COMPOUNDS AND THEIR APPLICATION IN PHARMACEUTICALS SUNSHINE LAKE PHARMA CO., LTD. (CN) 2016-07-21 US disclosed
US-20160206616-A1 DIHYDROPYRIMIDINE COMPOUNDS AND THEIR APPLICATION IN PHARMACEUTICALS SUNSHINE LAKE PHARMA CO., LTD. (CN) 2016-07-21 US disclosed
WO-2015074546-A1 DIHYDROPYRIMIDINE COMPOUNDS AND THEIR APPLICATION IN PHARMACEUTICALS SUNSHINE LAKE PHARMA CO., LTD. (CN) 2015-05-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160206616-A1 DIHYDROPYRIMIDINE COMPOUNDS AND THEIR APPLICATION IN PHARMACEUTICALS DPYD, SLC10A1, HPRT1 NR1H2 781/4885NR1H3 841/4885CCR2 3894/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.